• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用质量源于设计方法开发并验证用于测定胶囊中雷贝拉唑和左舒必利的超高效液相色谱法

Development and Validation of a UPLC Method by the QbD-Approach for the Estimation of Rabeprazole and Levosulpiride from Capsules.

作者信息

Thummala Veera Raghava Raju, Seshadri Raja Kumar, Tharlapu Satya Sankarsana Jagan Mohan, Ivaturi Mrutyunjaya Rao, Nittala Someswara Rao

机构信息

Analytical Research and Development, Integrated Product Development, Dr. Reddy's Laboratories Ltd., Bachupally, Hyderabad-500 072, India.

School of Chemistry, Andhra University, Visakhapatnam-530003, A.P., India.

出版信息

Sci Pharm. 2014 Jan 16;82(2):307-26. doi: 10.3797/scipharm.1310-17. Print 2014 Apr-Jun.

DOI:10.3797/scipharm.1310-17
PMID:24959404
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4065125/
Abstract

Statistical experimental design was used to optimize the chromatographic separations of two pharmaceutical compounds from their respective potential impurities. A fractional factorial design was utilized to study the effects of pH, organic solvent in mobile phases A&B, and flow rate on the resolution of Rabeprazole and Rabeprazole Sulfone, which had closely eluting peaks. A desirability function applied to the optimized conditions predicted the peak resolution between 2.2 and 2.7 for the Rabeprazole & Rabeprazole Sulfone impurity. The chromatographic method employed an Acquity UPLC, BEH C18 column (100 × 2.1 mm i.d., 1.7 μm particle size) with the mobile phase consisting of a phosphate buffer, pH 6.5, and acetonitrile in a gradient program. The flow rate and injection volumes were 0.45 mL/min & 5 μl, respectively, and detection was done at 254 nm. The chromatographic method was validated for linearity, accuracy, precision, specificity, and ruggedness according to ICH guidelines. The results clearly showed that the quality by design concept could be effectively applied to optimize a UPLC chromatographic method with fewer trials and error-free experimentation.

摘要

采用统计实验设计来优化两种药物化合物与其各自潜在杂质的色谱分离。利用析因设计研究pH值、流动相A和B中的有机溶剂以及流速对雷贝拉唑和雷贝拉唑砜分辨率的影响,这两种物质的洗脱峰很接近。应用合意函数于优化条件,预测雷贝拉唑与雷贝拉唑砜杂质之间的峰分辨率在2.2至2.7之间。该色谱方法采用Acquity UPLC、BEH C18柱(内径100×2.1 mm,粒径1.7μm),流动相由pH 6.5的磷酸盐缓冲液和乙腈组成,采用梯度洗脱程序。流速和进样体积分别为0.45 mL/min和5μl,检测波长为254 nm。根据ICH指南对该色谱方法的线性、准确度、精密度、特异性和耐用性进行了验证。结果清楚地表明,设计质量理念可以有效地应用于以较少的试验和无错误实验来优化UPLC色谱方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/91e61b77550e/scipharm.2014.82.307f7c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/8427b671a0b4/scipharm.2014.82.307f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/318ff93f42d2/scipharm.2014.82.307f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/c0b0d6ebab92/scipharm.2014.82.307f3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/4625a3f3fcd4/scipharm.2014.82.307f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/3e85259f9947/scipharm.2014.82.307f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/bb2ec837f33b/scipharm.2014.82.307f6a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/e4886c6be48d/scipharm.2014.82.307f6b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/879a683c12f1/scipharm.2014.82.307f6c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/5a2574fec6f7/scipharm.2014.82.307f7a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/3caf4c53efec/scipharm.2014.82.307f7b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/91e61b77550e/scipharm.2014.82.307f7c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/8427b671a0b4/scipharm.2014.82.307f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/318ff93f42d2/scipharm.2014.82.307f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/c0b0d6ebab92/scipharm.2014.82.307f3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/4625a3f3fcd4/scipharm.2014.82.307f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/3e85259f9947/scipharm.2014.82.307f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/bb2ec837f33b/scipharm.2014.82.307f6a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/e4886c6be48d/scipharm.2014.82.307f6b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/879a683c12f1/scipharm.2014.82.307f6c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/5a2574fec6f7/scipharm.2014.82.307f7a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/3caf4c53efec/scipharm.2014.82.307f7b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb53/4065125/91e61b77550e/scipharm.2014.82.307f7c.jpg

相似文献

1
Development and Validation of a UPLC Method by the QbD-Approach for the Estimation of Rabeprazole and Levosulpiride from Capsules.采用质量源于设计方法开发并验证用于测定胶囊中雷贝拉唑和左舒必利的超高效液相色谱法
Sci Pharm. 2014 Jan 16;82(2):307-26. doi: 10.3797/scipharm.1310-17. Print 2014 Apr-Jun.
2
Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Process-Related Impurities and Degradation Products of Rabeprazole Sodium in Pharmaceutical Formulation.一种用于测定药物制剂中雷贝拉唑钠工艺相关杂质和降解产物的稳定性指示反相高效液相色谱法的开发与验证
Sci Pharm. 2013 Mar 17;81(3):697-711. doi: 10.3797/scipharm.1301-25. Print 2013 Jul-Sep.
3
Novel Validated Stability-Indicating UPLC Method for the Estimation of Naproxen and its Impurities in Bulk Drugs and Pharmaceutical Dosage Form.用于原料药和药物剂型中萘普生及其杂质测定的新型经验证的稳定性指示超高效液相色谱法
Sci Pharm. 2012 Oct-Dec;80(4):965-76. doi: 10.3797/scipharm.1207-12. Epub 2012 Sep 9.
4
A Novel, Validated Stability-Indicating UPLC Method for the Estimation of Lansoprazole and its Impurities in Bulk Drug and Pharmaceutical Dosage Forms.一种用于原料药及药物制剂中兰索拉唑及其杂质测定的新型、经过验证的稳定性指示超高效液相色谱法。
Sci Pharm. 2013 Jan-Mar;81(1):183-93. doi: 10.3797/scipharm.1210-09. Epub 2012 Dec 3.
5
Using an innovative Quality-by-Design approach for development of a stability indicating UHPLC method for ebastine in the API and pharmaceutical formulations.采用创新的质量源于设计方法开发埃巴斯汀原料药及其制剂的稳定性指示 UHPLC 方法。
J Pharm Biomed Anal. 2013 May 5;78-79:65-74. doi: 10.1016/j.jpba.2013.01.032. Epub 2013 Jan 31.
6
[Analysis of teicoplanin impurities by two-dimensional ultra performance liquid chromatography-quadrupole/time-of-flight mass spectrometry].二维超高效液相色谱-四极杆/飞行时间质谱法分析替考拉宁杂质
Se Pu. 2023 Feb;41(2):195-204. doi: 10.3724/SP.J.1123.2022.03044.
7
Development and validation of a high throughput UPLC-MS/MS method for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma.一种用于同时定量测定人血浆中埃索美拉唑、雷贝拉唑和左舒必利的高通量超高效液相色谱-串联质谱法的开发与验证
J Pharm Anal. 2016 Jun;6(3):190-198. doi: 10.1016/j.jpha.2016.01.001. Epub 2016 Jan 8.
8
Simultaneous Determination of Sitagliptin Phosphate Monohydrate and Metformin Hydrochloride in Tablets by a Validated UPLC Method.采用验证的超高效液相色谱法同时测定片剂中磷酸西格列汀一水合物和盐酸二甲双胍的含量。
Sci Pharm. 2012 Jan-Mar;80(1):139-52. doi: 10.3797/scipharm.1110-13. Epub 2011 Dec 12.
9
Development of a rapid and validated stability-indicating UPLC-PDA method for concurrent quantification of impurity profiling and an assay of ipratropium bromide and salbutamol sulfate in inhalation dosage form.建立一个快速且经过验证的稳定性指示 UPLC-PDA 方法,用于同时定量测定杂质谱和吸入剂型中溴化异丙托品和硫酸沙丁胺醇的含量。
Ann Pharm Fr. 2023 Mar;81(2):300-314. doi: 10.1016/j.pharma.2022.09.002. Epub 2022 Sep 17.
10
Development and Validation of a Stability-Indicating RP-UPLC Method for Determination of Rosuvastatin and Related Substances in Pharmaceutical Dosage Form.用于测定药物剂型中瑞舒伐他汀及其相关物质的稳定性指示反相超高效液相色谱法的开发与验证
Sci Pharm. 2012 Apr-Jun;80(2):393-406. doi: 10.3797/scipharm.1201-09. Epub 2012 Mar 26.

引用本文的文献

1
Development and validation of a reversed-phase HPLC-UV method for simultaneous determination of levosulpiride and omeprazole in human plasma: Applicability of the method for evaluation of pharmacokinetic drug-drug interactions.建立并验证一种反相高效液相色谱-紫外检测法,用于同时测定人血浆中左舒必利和奥美拉唑的浓度:该方法用于评价药代动力学药物相互作用的适用性。
PLoS One. 2024 Aug 29;19(8):e0309453. doi: 10.1371/journal.pone.0309453. eCollection 2024.

本文引用的文献

1
Expanding the term "Design Space" in high performance liquid chromatography (I).扩展高效液相色谱中的“设计空间”术语(一)。
J Pharm Biomed Anal. 2011 Dec 15;56(5):874-9. doi: 10.1016/j.jpba.2011.04.015. Epub 2011 Apr 22.
2
Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction.采用固相萃取-高效液相色谱法测定雷贝拉唑对映体及其代谢产物。
J Pharm Biomed Anal. 2006 May 3;41(2):565-70. doi: 10.1016/j.jpba.2005.12.016. Epub 2006 Jan 18.
3
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of rabeprazole in human plasma.
用于定量测定人血浆中雷贝拉唑的液相色谱/串联质谱分析法的开发。
Rapid Commun Mass Spectrom. 2005;19(16):2321-4. doi: 10.1002/rcm.2066.
4
Spectrophotometric and chromatographic determination of rabeprazole in presence of its degradation products.
J Pharm Biomed Anal. 2003 Feb 26;31(2):229-42. doi: 10.1016/s0731-7085(02)00445-4.
5
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.综述文章:基于雷贝拉唑的疗法根除幽门螺杆菌
Aliment Pharmacol Ther. 2002 Mar;16 Suppl 1:31-3. doi: 10.1046/j.1365-2036.2002.0160s1031.x.
6
Chiral analysis of selected dopamine receptor antagonists in serum using capillary electrophoresis with cyclodextrin additives.使用含环糊精添加剂的毛细管电泳法对血清中选定的多巴胺受体拮抗剂进行手性分析。
J Pharm Biomed Anal. 2000 Sep;23(4):735-43. doi: 10.1016/s0731-7085(00)00356-3.
7
Selective determination of sultopride in human plasma using high-performance liquid chromatography with ultraviolet detection and particle beam mass spectrometry.
J Chromatogr B Biomed Sci Appl. 1997 Mar 7;690(1-2):153-9. doi: 10.1016/s0378-4347(96)00423-9.
8
Disposition of enantiomers of sulpiride in humans and rats.舒必利对映体在人和大鼠体内的处置情况。
Biopharm Drug Dispos. 1993 Aug;14(6):475-81. doi: 10.1002/bdd.2510140603.
9
Levosulpiride: a review of its clinical use in psychiatry.
Pharmacol Res. 1995 Feb;31(2):95-101. doi: 10.1016/1043-6618(95)80053-0.
10
Pharmacotoxicological aspects of levosulpiride.左舒必利的药物毒理学方面。
Pharmacol Res. 1995 Feb;31(2):81-94. doi: 10.1016/1043-6618(95)80052-2.